AzTrials
AzTrials

Juvenile Rheumatoid ArthritisNCT00090571

Juvenile Rheumatoid Arthritis Research Registry

An observational study of Juvenile Rheumatoid Arthritis, run by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Juvenile rheumatoid arthritis (JRA) is the most common chronic inflammatory disease in children, and may be related to genetics. Having two siblings who both have JRA in one family is rare. The purpose of this registry is to collect patient information and blood samples from qualifying JRA siblings and their families. Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
Conditions the study is for
Juvenile Rheumatoid Arthritis
How many people
200 participants
Where
1 siteUnited States
Study dates
Oct 1994to Sep 2009
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: siblings affected with JIA

Who may be able to join

  • At least two members of a family diagnosed with juvenile rheumatoid arthritis (JRA)
  • Informed consent from the family indicating willingness to participate in the registry

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229-3039

Other trials in United States

About this study

Official title: Research Registry for Juvenile Arthritis

Juvenile rheumatoid arthritis (JRA) is the most common chronic inflammatory disease in children, and may be related to genetics. Having two siblings who both have JRA in one family is rare. The purpose of this registry is to collect patient information and blood samples from qualifying JRA siblings and their families. The goal of the registry is to further understanding of JRA as related to genetics.

Read the detailed description

JRA is the most common chronic inflammatory pediatric rheumatic disease. JRA may be related to a complex genetic trait. It is rare to have two or more affected siblings, or sibpairs, within one family. The JRA ASP (Affected Sibpair) Registry is a nationwide effort and will collect information and blood samples from JRA sibpairs and their families. Unaffected family members (e.g., mother, father, and unaffected children) are also invited to participate.

Patients and their families may enroll in the registry in one of two ways: patients may contact the registry directly, or they may be referred to the registry through their physician. Once the family has qualified to join the registry, the family will be asked to complete a questionnaire on the medical history of their JRA-affected members. Physicians of the JRA-affected members will be asked to complete questionnaires about their patients' conditions. Family members will also be invited to provide a one-time blood sample. Information collected through the registry will help researchers identify genes involved in JRA susceptibility.

Keywords
JRA ASPs, Genomics
Medical subject headings
Arthritis, Juvenile

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT00090571
Study groupRoleWhat they receive
Sib PairsTwo or more biological siblings affected with JIA.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Aug 2004 (estimated)
  2. Study startOct 1994
  3. Primary completionSep 2009
  4. Study completionSep 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Family based
Time perspective
Prospective
Enrolment
200 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00090571
Sponsor's protocol ID
NIAMS-102
Other IDs
N01AR42272-8-0-1, NIAMS-102;N01-04-03
Status last verified
Sep 2022
First submitted
27 Aug 2004
Last updated
28 Sep 2022
Results posted
No
Data monitoring committee
No

Publications

  • Moroldo MB, Chaudhari M, Shear E, Thompson SD, Glass DN, Giannini EH. Juvenile rheumatoid arthritis affected sibpairs: extent of clinical phenotype concordance. Arthritis Rheum. 2004 Jun;50(6):1928-34. doi: 10.1002/art.20292.

    PubMed 15188369

  • Barnes MG, Aronow BJ, Luyrink LK, Moroldo MB, Pavlidis P, Passo MH, Grom AA, Hirsch R, Giannini EH, Colbert RA, Glass DN, Thompson SD. Gene expression in juvenile arthritis and spondyloarthropathy: pro-angiogenic ELR+ chemokine genes relate to course of arthritis. Rheumatology (Oxford). 2004 Aug;43(8):973-9. doi: 10.1093/rheumatology/keh224. Epub 2004 May 18.

    PubMed 15150433

  • Ogilvie EM, Fife MS, Thompson SD, Twine N, Tsoras M, Moroldo M, Fisher SA, Lewis CM, Prieur AM, Glass DN, Woo P. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum. 2003 Nov;48(11):3202-6. doi: 10.1002/art.11300.

    PubMed 14613283

  • Moroldo MB, Tague BL, Shear ES, Glass DN, Giannini EH. Juvenile rheumatoid arthritis in affected sibpairs. Arthritis Rheum. 1997 Nov;40(11):1962-6. doi: 10.1002/art.1780401107.

    PubMed 9365084

  • Prahalad S, Shear ES, Thompson SD, Giannini EH, Glass DN. Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis. Arthritis Rheum. 2002 Jul;46(7):1851-6. doi: 10.1002/art.10370.

    PubMed 12124869

  • Prahalad S, Ryan MH, Shear ES, Thompson SD, Glass DN, Giannini EH. Twins concordant for juvenile rheumatoid arthritis. Arthritis Rheum. 2000 Nov;43(11):2611-2. doi: 10.1002/1529-0131(200011)43:113.0.CO;2-T. No abstract available.

    PubMed 11083290

  • Prahalad S, Ryan MH, Shear ES, Thompson SD, Giannini EH, Glass DN. Juvenile rheumatoid arthritis: linkage to HLA demonstrated by allele sharing in affected sibpairs. Arthritis Rheum. 2000 Oct;43(10):2335-8. doi: 10.1002/1529-0131(200010)43:103.0.CO;2-W.

    PubMed 11037894

  • Hinks A, Ke X, Barton A, Eyre S, Bowes J, Worthington J, Thompson SD, Langefeld CD, Glass DN, Thomson W; UK Rheumatoid Arthritis Genetics Consortium; British Society of Paediatric and Adolescent Rheumatology Study Group. Association of the IL2RA/CD25 gene with juvenile idiopathic arthritis. Arthritis Rheum. 2009 Jan;60(1):251-7. doi: 10.1002/art.24187.

    PubMed 19116909

  • Zeft A, Shear ES, Thompson SD, Glass DN, Prahalad S. Familial autoimmunity: maternal parent-of-origin effect in juvenile idiopathic arthritis. Clin Rheumatol. 2008 Feb;27(2):241-4. doi: 10.1007/s10067-007-0778-8. Epub 2007 Nov 10.

    PubMed 17994193

  • Prahalad S, Bohnsack JF, Whiting A, Clifford B, Jorde LB, Guthery SL, Thompson SD, Glass DN, Bamshad MJ. Lack of association of functional CTLA4 polymorphisms with juvenile idiopathic arthritis. Arthritis Rheum. 2008 Jul;58(7):2147-52. doi: 10.1002/art.23602.

    PubMed 18576317

  • Prahalad S, Bohnsack JF, Jorde LB, Whiting A, Clifford B, Dunn D, Weiss R, Moroldo M, Thompson SD, Glass DN, Bamshad MJ. Association of two functional polymorphisms in the CCR5 gene with juvenile rheumatoid arthritis. Genes Immun. 2006 Sep;7(6):468-75. doi: 10.1038/sj.gene.6364317. Epub 2006 Jun 15.

    PubMed 16775617

  • Phelan JD, Thompson SD. Genomic progress in pediatric arthritis: recent work and future goals. Curr Opin Rheumatol. 2006 Sep;18(5):482-9. doi: 10.1097/01.bor.0000240359.30303.e4.

    PubMed 16896287

  • Phelan JD, Thompson SD, Glass DN. Susceptibility to JRA/JIA: complementing general autoimmune and arthritis traits. Genes Immun. 2006 Jan;7(1):1-10. doi: 10.1038/sj.gene.6364273.

    PubMed 16435022

  • Ferucci ED, Majka DS, Parrish LA, Moroldo MB, Ryan M, Passo M, Thompson SD, Deane KD, Rewers M, Arend WP, Glass DN, Norris JM, Holers VM. Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2005 Jan;52(1):239-46. doi: 10.1002/art.20773.

    PubMed 15641089

  • Bukulmez H, Fife M, Tsoras M, Thompson SD, Twine NA, Woo P, Olson JM, Elston RC, Glass DN, Colbert RA. Tapasin gene polymorphism in systemic onset juvenile rheumatoid arthritis: a family-based case-control study. Arthritis Res Ther. 2005;7(2):R285-90. doi: 10.1186/ar1480. Epub 2005 Jan 11.

    PubMed 15743475

Questions about this trial

What is this clinical trial studying?

An observational study of Juvenile Rheumatoid Arthritis, run by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00090571, which also lists 15 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2022.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in